Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Sanofi, GSK say COVID-19 vaccine booster candidate give good immune response

Wed, 15th Dec 2021 07:29

(Adds details throughout)

By Benoit Van Overstraeten

PARIS, Dec 15 (Reuters) - Sanofi and
GlaxoSmithKline said on Wednesday a single booster dose
of their COVID-19 vaccine candidate provided strong immune
responses, preliminary data from clinical trials show, a boost
for the drugmakers after lagging the vaccine race.

The French and British partners said they expected more
results of the late-stage Phase III study of their recombinant
adjuvanted COVID-19 vaccine candidate in the first quarter.

They plan to file booster data with regulatory authorities
following the Phase III results.

"The booster was well tolerated, with a safety profile
similar to currently approved COVID-19 vaccines. This is the
most comprehensive booster trial to date to explore boosting
across different vaccine technologies used for primary
vaccination", the companies said in a statement.

"To provide the necessary data to regulatory authorities for
the booster vaccine submission, the trial will continue to
accrue the number of events needed for analysis, with results
expected in Q1, 2022."

No safety concerns were identified.

The vaccine uses the same technology as one of Sanofi's
seasonal influenza vaccines coupled with an adjuvant, a
substance that acts as a booster to the shot, made by GSK.

The news provides some optimism for the companies after
falling behind rivals in the race for COVID-19 shots and big
delays with the development of this shot.

Last year, trials for the shot showed an insufficient immune
response in older people. The companies had said the vaccine
could be approved by the year-end after initially targeting the
first half of the year.

At the end of September, Sanofi dropped its plans for its
own mRNA-based COVID-19 vaccine because of the dominance
achieved by BioNTech-Pfizer and Moderna
in using the technology to fight the pandemic.

BOOSTER SHOT

The booster shot has been tested for all age groups and for
people who have received four of the most widely approved shots
- AstraZeneca, Johnson & Johnson, Moderna and
Pfizer/BioNTech - as part of their primary vaccine.

It was administered between four and ten months after a
complete primary vaccination schedule. The Omicron variant was
not circulating during the trial.

"Preliminary results from the VAT0002 clinical trial
investigating the safety and immunogenicity of the booster
showed neutralizing antibodies increased nine to 43-fold
regardless of the primary vaccine received (AstraZeneca, Johnson
& Johnson, Moderna, Pfizer/BioNTech) and for all age groups
tested", Sanofi said.

The company said this was the most "comprehensive" booster
trial to date as European countries grapple with a new wave of
COVID-19 infections fuelled by the Delta variant of the virus
and are gearing up for the new more contagious Omicron variant.

Sanofi also it was continuing "its contribution to global
public health needs" with the manufacturing of up to half a
billion doses from BioNTech/Pfizer, Moderna, and Johnson &
Johnson vaccines.

(Reporting by Benoit Van Overstraeten;
Writing by Josephine Mason
Editing by Tom Hogue and Louise Heavens)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.